Stock GALT GALECTIN THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
3.05 USD 0.00% Intraday chart for Galectin Therapeutics Inc. -5.57% +83.73%
May. 15 Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 29 Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
AQ
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
AQ
Galectin Therapeutics : Corporate Presentation, April 2024
PU
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension
AQ
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
AQ
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors
CI
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K
PU
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Stocks Set for -2-
DJ
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
AQ
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
AQ
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
AQ
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
AQ
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors
AQ
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GALT Stock
  4. News Galectin Therapeutics Inc.